Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Novartis AG (NYSE: NVS).

Full DD Report for NVS

You must become a subscriber to view this report.


Recent News from (NYSE: NVS)

Novartis' Kisqali extends PFS in late-stage breast cancer studies
Subgroup analyses from three Phase 3 MONALESSA studies evaluating Novartis' (NYSE: NVS ) Kisqali (ribociclib) plus endocrine therapy in patients with HR+/HER2- advanced breast cancer showed a treatment benefit. The data are being presented at the San Antonio Breast Cancer Symposium. Mor...
Source: SeekingAlpha
Date: December, 10 2018 07:38
Conatus And Emricasan In NASH Cirrhotic Portal Hypertension: The Overlooked Therapeutic Promise
"Nothing can dim the light that shines from within" - Maya Angelou Introduction Conatus Pharmaceuticals ( CNAT ) is a small cap ($52M) clinical stage biopharma. Emricasan, a dual anti-apoptotic/anti-inflammatory oral irreversible pan-caspase inhibitor, is its lead investigative P...
Source: SeekingAlpha
Date: December, 10 2018 05:59
Tencent Music, Starbucks And Under Armour In Focus (Stocks To Watch Podcast)
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f...
Source: SeekingAlpha
Date: December, 09 2018 07:27
ADMP And Sandoz Announce Plans For SYMJEPI Launch
Sources Investors finally received updates from Adamis ( ADMP ) and Sandoz about the planned launch of SYMJEPI. The Adamis press release was short, but provided some insight on the company’s recent actions to support the launch. According to the press release, “Manufact...
Source: SeekingAlpha
Date: December, 07 2018 13:24
Conatus May Still Have A Path Forward After Latest Phase 2b Data
Recently, Conatus Pharmaceuticals ( CNAT ) announced results from its phase 2b ENCORE-PH study treating patients with NASH cirrhosis portal hypertension. The primary endpoint for the overall trial wasn't met. However, I believe that the company still has a path forward for a subpopulation ...
Source: SeekingAlpha
Date: December, 07 2018 08:50
Celgene Doesn't Want To Be Left Out, Posts Promising JCAR017 Data
Recently, Celgene ( CELG ) announced preliminary data from its study treating patients with relapsed/refractory (r/r) chronic lymphocytic leukemia ((CLL)) and small lymphocytic lymphoma ((SLL)). The data shown was from the dose escalation part of an ongoing, open-label multicenter phase ...
Source: SeekingAlpha
Date: December, 06 2018 19:46
Altimmune: Suppressed, Immature, Or Dormant?
2018 has been a volatile year for Altimmune ( ALT ) from start to finish. The company experienced mixed results in clinical trials as well as changes management positions. Unfortunately, the share price has taken the brunt of the losses and has gained little from the wins. After a reverse spli...
Source: SeekingAlpha
Date: December, 05 2018 15:22
Biohaven Pharma up 17% on positive data on migraine med Zydis
Thinly traded Biohaven Pharmaceutical Holding Company ( BHVN +17.1% ) is up on more than double normal volume following its announcement of topline data from a Phase 3 clinical trial, BHV3000-303 , evaluating lead candidate Zydis (rimegepant) orally dissolving tablet for the acute treat...
Source: SeekingAlpha
Date: December, 03 2018 12:05
Novartis in-licences radiotherapy candidate from Fujifilm Toyama Chemical
Novartis (NYSE: NVS ) unit Advanced Accelerator Applications S.A. (AAA) inks an exclusive option and license agreement with FUJIFILM Toyama Chemical for global development and commercialization rights (ex-Japan) to FF-10158 for oncology indications. More news on: Novartis AG, Healthcare ...
Source: SeekingAlpha
Date: December, 03 2018 07:42
FDA accepts Novartis' marketing application for SMA Type 1 gene therapy AVXS-101
The FDA accepts under Priority Review Novartis' (NYSE: NVS ) marketing application seeking approval for gene therapy AVXS-101 for the treatment of spinal muscular atrophy (SMA) Type 1. The agency's action date is in May 2019. More news on: Novartis AG, Biogen Inc., Ionis Pharmaceuticals,...
Source: SeekingAlpha
Date: December, 03 2018 07:32

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1485.0485.3085.4084.791,982,378
2017-02-0272.7673.0873.2472.724,212,413
2017-02-0173.1173.4273.4572.745,323,274
2017-01-3172.4973.9273.9572.253,501,744
2017-01-3071.9572.3072.49571.814,098,043

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1016,68047,37835.2062Short
2018-12-0737,61771,76952.4140Short
2018-12-0620,65945,07745.8305Short
2018-12-0413,84456,94624.3108Cover
2018-12-036,04429,21220.6901Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NVS.


About Novartis AG (NYSE: NVS)

Logo for Novartis AG (NYSE: NVS)

Not available

 

Contact Information

 

 

Current Management

  • Daniel Vasella / President
  • Raymond Breu / CFO

Current Share Structure

  • Market Cap: $176,358,439,574 - 05/25/2018
  • Issue and Outstanding: 2,317,456,499 - 12/31/2017

 


Recent Filings from (NYSE: NVS)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: September, 06 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 29 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 23 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 18 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 29 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 29 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 01 2018

 

 


Daily Technical Chart for (NYSE: NVS)

Daily Technical Chart for (NYSE: NVS)


Stay tuned for daily updates and more on (NYSE: NVS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: NVS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NVS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NVS and does not buy, sell, or trade any shares of NVS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/